Epigenetic drugs against cancer: an evolving landscape
- 1.6k Downloads
Alteration of the chromatin orchestra seems to play a critical role in cancer. In recent years, in-depth studies of epigenetic machinery and its deregulation have led to the development and use of a wide range of modulatory molecules directed not only at chromatin enzymes (histone acetyltransferases, histone deacetylases, histone methyltransferases, histone demethylases and DNA methyltransferases) but also toward the emerging class of chromatin-associated proteins, so-called “histone readers.” Chromatin modifiers are attractive therapeutic targets for the development of new cancer therapies. Many are currently approved by the US Food and Drug Administration and used to treat different malignancies. Specifically, inhibitors of DNA methyltransferases, such as azacitidine and decitabine, have been approved for the treatment of myelodysplastic syndrome, while inhibitors of histone deacetylases, including vorinostat and romidepsin, have been approved for cutaneous T-cell lymphoma. The bromodomain and extra-terminal inhibitors JQ1, IBET762 and IBET151 have performed extremely well in preclinical settings, suggesting that they may be promising molecules for the treatment of some type of tumors. This review focuses on epidrugs and their possible application, with particular emphasis on their mechanism of action as well as their present status in clinical and preclinical trials.
KeywordsEpigenetics Chromatin modulation Cancer Drug discovery
This work was supported by: EU, Blueprint project no. 282510; the Italian Flag Project: EPIGEN; AIRC No. 11812; PRIN-2012. We apologize to the authors whose work we could not cite due to reference restrictions. We wish to thank C. Fisher for linguistic editing of the manuscript.
Conflict of interest
The authors declare no conflict of interest.
- Balasubramanyam K, Varier RA, Altaf M et al (2004) Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 279(49):51163–51171. doi: 10.1074/jbc.M409024200 PubMedGoogle Scholar
- Fredly H, Gjertsen BT, Bruserud O (2013) Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenet 5(1):12. doi: 10.1186/1868-7083-5-12 Google Scholar
- George P, Bali P, Annavarapu S et al (2005) Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105(4):1768–1776. doi: 10.1182/blood-2004-09-3413 PubMedGoogle Scholar
- Karthik S, Sankar R, Varunkumar K, Ravikumar V (2014) Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. Biomed Pharmacother 68(3):327–334. doi: 10.1016/j.biopha.2014.01.002 PubMedGoogle Scholar
- Klisovic RB, Stock W, Cataland S et al (2008) A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res 14(8):2444–2449. doi: 10.1158/1078-0432.CCR-07-1320 PubMedGoogle Scholar
- Kurundkar D, Srivastava RK, Chaudhary SC et al (2013) Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol Appl Pharmacol 266(2):233–244. doi: 10.1016/j.taap.2012.11.002 PubMedCentralPubMedGoogle Scholar
- Maes T, Tirapu I, Mascaro C et al (2013) Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia. J Clin Oncol 31(15):e13543Google Scholar
- Momparler RL, Bovenzi V (2000) DNA methylation and cancer. J Cell Physiol 183(2):145–154. doi: 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V PubMedGoogle Scholar
- Patutina OA, Mironova NL, Vlassov VV, Zenkova MA (2009) New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids. Acta Nat 1(2):44–60Google Scholar
- Savickiene J, Treigyte G, Jazdauskaite A, Borutinskaite VV, Navakauskiene R (2012) DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling. Cell Biol Int 36(11):1067–1078. doi: 10.1042/CBI20110649 PubMedGoogle Scholar
- Schaefer M, Pollex T, Hanna K, Tuorto F, Meusburger M, Helm M, Lyko F (2010) RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage. Genes Dev 24(15):1590–1595. doi: 10.1101/gad.586710
- Terao Y, Nishida J, Horiuchi S et al (2001) Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int J Cancer J Int Du Cancer 94(2):257–267Google Scholar